abstract |
The present invention provides PD-L1 antibody secreting anti-mesothelin chimeric antigen receptor (CAR)-T cells for tumor immunotherapy, the CAR-T cells co-express anti-PD-L1 fusion antibodies, nonfunctional EGFR and CAR, wherein, the anti-PD-L1 fusion antibody is formed by linking an anti-PD-L1 single chain antibody to an IgG1Fc fragment containing amino acid mutation. |